13 May 2020 --- Royal DSM’s investment arm, DSM Venturing is a cornerstone investor in a €10 million (US$10.8 million) funding round for Oxford-based life science company Phynova. The latter is working toward fulfilling significant commercial orders for its Reducose technology in Europe, China and North America. The ingredient addresses the global issue of excessive blood-glucose levels, which can lead to severe conditions such as diabetes, obesity and cardiovascular disease (CVD). It holds a wide range of applications such as in supplements, functional foods and beverages for those seeking to modulate glycemic index.
